PHVS: Pharvaris Pharma Fair Value Consensus
Pharvaris N.V. (PHVS) is developing its scaling potential by transitioning from injections to tablet forms of hereditary angioedema therapy, which expands patient reach. Stock options ensure the stability of the R&D team, while the company is actively recruiting sales experts. The business relies on the non-cyclical demand for orphan drugs, and the current metric stands at 57.78. This chart of share price dynamics confirms the company's resilience to crises.
Analytical breakdowns for Pharvaris Corp (PHVS)
- share price and expert price forecast:
- market capitalization information:
- book capitalization indicators:
- business debt structure and liquidity details:
Aggregate Debt to Equity Pharvaris N.V.|PHVS - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital Pharvaris Pharma|PHVS - Company Aggregate Debts|Debts to Book Capitalization Pharvaris Corp|PHVS - Company Long-Term Debt|Company Short-Term Loans and Borrowings Pharvaris|Quick Liquidity Indicator pharvaris.com
- financial results and valuation multiples details:
PHVS - Net Profit|Projected Future Earnings Pharvaris N.V.|PHVS - Price to Earnings Ratio|Future Price to Earnings Multiple Pharvaris NV|PHVS - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Pharvaris Corp|PHVS - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months Pharvaris|PHVS - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months pharvaris.com|PHVS - Net earnings per share growth this year|Earnings growth forecast for next year Pharvaris N.V.
General company analysis:PHVS pharvaris.com
The asset's fundamental value is based on operational resilience and the growth potential of cash flows. This indicator aggregates the average price targets of leading investment houses, reflecting the dynamics of market expectations in real time. For Pharvaris N.V. (PHVS), this confirms the value of its exclusive status as a provider of rare disease therapies. The stability of the share price projected by experts proves the viability of the innovative drug ecosystem. Analyzing this line allows for an assessment of the risk of business overvaluation.
Competitors of Pharvaris N.V.
ARGX: Forecast Levels Chart|Analyst Consensus Forecast BNTX (BioNTech)|Fair Value Consensus ABVX|ADMA: Consensus Target|PTGX: Price Target Chart|Immunovant, Inc. (IMVT) - Price Target Chart|KNSA - Analyst Median Target|Price Target Chart Grifols|Adaptive Biotech - Forecast Levels Chart|Analyst Consensus Forecast CLDX|AUPH (Aurinia Corp) - Fair Value Consensus|Analyst Consensus Forecast BCRX (BioCryst)|Analyst Consensus Forecast veratx.com VERA|DNTH - Price Target Chart|Fair Value Consensus ABCL (abcellera.com)|Tourmaline Corp (TRML) - Price Target Chart|Consensus Target Precigen Corp|PHAR (Pharming Group N.V.) - Analyst Consensus Forecast|Analyst Consensus Forecast nektar.com|Consensus Target UPB (Upstream Bio)|ZBIO (Zenas Bio) - Fair Value Consensus|Analyst Consensus Forecast IMNM (Immunome Corp)|Analyst Median Target Gossamer Bio Corp. (GOSS)|KALV - Price Target Chart|septerna.com (SEPN) - Consensus Target|Pieris Pharmaceuticals, Inc. (PVLA) - Price Target Chart|Consensus Target Savara Inc|Consensus Target RIGL|Analyst Consensus Forecast AnaptysBio Inc.|Price Target Chart Astria Therapeutics (ATXS)|engene.com - Broker Consensus Forecast|Analyst Consensus Forecast RAPT (RAPT Therapeutics, Inc.)|Aerovate Therapeutics, Inc. (JBIO) - Average Forecast Price|ACRS - Price Target Chart|Forecast Levels Chart KYTX|TLSA: Analyst Consensus Forecast|cabalettabio.com - Fair Value Consensus|VTYX (Ventyx Biosciences, Inc.) - Analyst Consensus Forecast|Analyst Consensus Forecast Theratechnologies, Inc.|Price Target Chart Avalo Therapeutics Inc. (AVTX)|ELDN (Eledon Pharmaceuticals, Inc) - Fair Value Consensus|Agenus - Consensus Target|climbbio.com - Price Target Chart|Zura Bio Limited - Analyst Consensus Forecast|ATYR - Analyst Consensus Forecast|adagene.com (ADAG) - Price Target Chart|Ikena Oncology - Fair Value Consensus|STTK (Shattuck Labs Inc) - Analyst Consensus Forecast|Equillium Bio (EQ) - Analyst Median Target|Price Target Chart Connect Biopharma (CNTB)|Analyst Median Target immunic-therapeutics.com|Atara Bio - Consensus Target|Fair Value Consensus IFRX|XFOR - Price Target Chart|ACET (Adicet Bio) - Broker Consensus Forecast|CELU (celularity.com) - Consensus Target|INMB - Analyst Median Target|Consensus Target BRNS|Price Target Chart KZR|Consensus Target SABS (SAB Biotherapeutics)|Analyst Median Target akaritx.com|Price Target Chart Enlivex Therapeutics Ltd. ENLV|QTTB (Q32 Bio Inc) - Forecast Levels Chart|GeoVax Labs Inc - Analyst Consensus Forecast|Fair Value Consensus EDSA (Edesa Biotech Corp)|IBIO (iBio, Inc.) - Consensus Target|CARM (Carisma Therapeutics Inc.) - Price Target Chart|Price Target Chart XTL Biopharmaceuticals Ltd.|Bolt Bio (BOLT) - Analyst Median Target|Price Target Chart HCW Biologics Inc. (HCWB)|APVO: Forecast Levels Chart|Analyst Consensus Forecast AIM (AIM ImmunoTech)|Fair Value Consensus ADTX|GRI Bio - Analyst Consensus Forecast|XRTX - Analyst Consensus Forecast|ReShape Lifesciences (HIND) - Price Target Chart|Revelation Biosciences Corp - Fair Value Consensus|Price Target Chart Indaptus Therapeutics|Consensus Target scinai.com (SCNI)|Analyst Consensus Forecast CALI|Analyst Consensus Forecast affimed.com (AFMD)|Allakos - Consensus Target|Fair Value Consensus HOOK|IGM Bio - Analyst Consensus Forecast|Analyst Median Target iteostherapeutics.com ITOS|Ocean Biomedical (OCEA) - Price Target Chart|Consensus Target TC BioPharm (Holdings) Plc|Price Target Chart Third Harmonic Bio, Inc
